Radiomics and Artificial Intelligence in Tumor and Normal Organ Imaging
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".
Deadline for manuscript submissions: 31 July 2026 | Viewed by 23
Special Issue Editor
2. Department of Basic and Translational Research, BC Cancer Research Institute, Vancouver, BC, Canada
Interests: radiomics; AI; precision oncology; adaptive radiotherapy; imaging biomarkers
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Recent advances in radiomics and artificial intelligence (AI) have transformed medical imaging by enabling quantitative, data-driven characterization of both tumors and normal organs. AI-based imaging biomarkers derived from multimodal and longitudinal imaging provide new opportunities for improved tumor phenotyping, treatment response assessment, and outcome prediction. At the same time, quantitative analysis of normal organs has gained increasing importance for toxicity prediction, organ-at-risk modeling, and personalization of oncologic therapies.
This Special Issue aims to highlight methodological developments, clinical applications, and translational studies that advance radiomics and AI for integrated tumor and normal organ imaging. Topics of interest include machine learning and deep learning methods, imaging biomarker validation, robustness and reproducibility, interpretability, and clinical integration across diagnostic and therapeutic workflows. Original research articles, reviews, and methodological studies contributing to precision oncology through AI-driven imaging are particularly encouraged.
Dr. Hamid Abdollahi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- radiomics
- artificial intelligence
- tumor imaging
- normal organ imaging
- quantitative imaging biomarkers
- precision oncology
- treatment response assessment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
